Drug developers have successfully tackled general anxiety with a number of innovations. But social anxiety disorder, which can trigger debilitating fear, self-consciousness or nervousness during ...
A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program ...
Chinese clinical trials have become synonymous with speed and savings, but questions have surfaced about the price of those advantages. Reports surfaced over the summer of three deaths in Chinese ...
Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions.
Gilead’s new “Up to Date” campaign uses humor and dating scenarios to reach Black communities amid persistent gaps in HIV ...
Gilead is growing its HIV franchise with a fresh FDA nod. The agency OK’d a novel medication last week that combines two Gilead HIV treatments into a single pill as an option for patients who want to ...
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management ...
More than 25 years after it was declared eliminated, measles has surged back. But drug R&D is still in early stages and up ...
CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results